Chemistry & Life Sciences

Expert Statement: Gordon Bates, Lonza

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Greg Behar, Recipharm

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Gavin Murdoch, Abzena

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Jordi Robinson, Navin Molecular

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Tom Sellig, Adare Pharma Solutions

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Christoph Schaffrath, Lanxess

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Yu Lu, WuXi STA

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Neil Jones, Aenova

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.